---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-042511"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2024-10-25T23:59:59+00:00"
generated_at: "2026-05-30T10:09:11.213203+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Mira Pharmaceuticals' Ketamir-2 shows 60% greater efficacy than gabapentin in preclinical neuropathy study

## Summary
- Ketamir-2 demonstrated 60% greater efficacy than FDA-approved gabapentin in a preclinical model of chemotherapy-induced neuropathic pain.
- Company plans additional preclinical studies targeting diabetic neuropathy and PTSD.
- Exploring government funding opportunities to support the development program.

## SEC filing metadata
- accession: 0001493152-24-042511
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2024-10-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000149315224042511/0001493152-24-042511-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000149315224042511/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-042511
- JSON: https://secwatch.observer/filing/0001493152-24-042511.json
- Plain text: https://secwatch.observer/filing/0001493152-24-042511.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.